Justyna Mierzynska1, Mekdes Taye1, Madeline Pe1, Corneel Coens1, Francesca Martinelli1, Katarzyna Pogoda2, Galina Velikova3, Vesna Bjelic-Radisic4, Fatima Cardoso5, Etienne Brain6, Michail Ignatiadis7, Martine Piccart7, Geertjan Van Tienhoven8, Robert Mansel9, Hans Wildiers10, Andrew Bottomley11. 1. Department of Quality of Life, European Organization of Research and Treatment for Cancer, Brussels, Belgium. 2. Department of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland. 3. Leeds Institute of Medical Research, St James's University of Leeds and Leeds Teaching Hospitals, Leeds, United Kingdom. 4. Breast Unit, Helios University Clinic Wuppertal & Witten/Herdecke University, Wuppertal & Witten, Germany. 5. Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal. 6. Department of Medical Oncology, Institut Curie, Paris & Saint Cloud, France. 7. Department of Medical Oncology, Jules Bordet Institute, Université Libre de Bruxeles, Brussels, Belgium. 8. Department of Radiation Oncology, Amsterdam UMBC, Location AMC, Amsterdam, the Netherlands. 9. Department of Surgery, Cardiff University, Cardiff, United Kingdom. 10. Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium. 11. Department of Quality of Life, European Organization of Research and Treatment for Cancer, Brussels, Belgium. Electronic address: andrew.bottomley@eortc.org.
Abstract
BACKGROUND: Considering the worldwide incidence of breast cancer (BC) and the importance of health-related quality of life (HRQoL) assessment, there is a growing need to have accurate and up-to-date reference values (RVs). RVs are useful for the design of randomised controlled trials (RCTs) and as benchmarks for comparison of cancer RCTs and health care interventions. This study aimed to provide RVs for the QLQ-C30 in early BC (EBC) and metastatic BC (MBC). General patterns of main results from the EORTC dataset (main dataset) were compared with the PDS dataset (comparison dataset) to see whether they would be consistent across pre-defined covariates. METHODS: European Organization for Research and Treatment of Cancer (EORTC) (main dataset) and Project Data Sphere (PDS) (comparison dataset) were searched to identify BC RCTs where baseline HRQoL (before treatment) was assessed with the QLQ-C30. RVs were calculated and stratified by disease stage, age, and when available, performance status (PS), comorbidity and region. RVs were reported using descriptive statistics. RESULTS: Data from three EORTC (n = 4115) and three PDS RCTs (n = 1406) were included in the analysis. While EBC patients presented better HRQoL with high baseline functioning scores and low prevalence of symptoms, MBC patients reported worse HRQoL with lower functioning scores and more prevalence of symptoms. In MBC, poor PS and presence of comorbidities reflected worse baseline HRQoL. No consistent differences were found for age and countries. CONCLUSION: These up-to-date RVs for the EORTC QLQ-C30 in BC show differences in HRQoL scores between stages, PS, and comorbidities. These findings, supported by an independent dataset, will help the clinical interpretation of scores for BCpatients.
BACKGROUND: Considering the worldwide incidence of breast cancer (BC) and the importance of health-related quality of life (HRQoL) assessment, there is a growing need to have accurate and up-to-date reference values (RVs). RVs are useful for the design of randomised controlled trials (RCTs) and as benchmarks for comparison of cancer RCTs and health care interventions. This study aimed to provide RVs for the QLQ-C30 in early BC (EBC) and metastatic BC (MBC). General patterns of main results from the EORTC dataset (main dataset) were compared with the PDS dataset (comparison dataset) to see whether they would be consistent across pre-defined covariates. METHODS: European Organization for Research and Treatment of Cancer (EORTC) (main dataset) and Project Data Sphere (PDS) (comparison dataset) were searched to identify BC RCTs where baseline HRQoL (before treatment) was assessed with the QLQ-C30. RVs were calculated and stratified by disease stage, age, and when available, performance status (PS), comorbidity and region. RVs were reported using descriptive statistics. RESULTS: Data from three EORTC (n = 4115) and three PDS RCTs (n = 1406) were included in the analysis. While EBC patients presented better HRQoL with high baseline functioning scores and low prevalence of symptoms, MBC patients reported worse HRQoL with lower functioning scores and more prevalence of symptoms. In MBC, poor PS and presence of comorbidities reflected worse baseline HRQoL. No consistent differences were found for age and countries. CONCLUSION: These up-to-date RVs for the EORTC QLQ-C30 in BC show differences in HRQoL scores between stages, PS, and comorbidities. These findings, supported by an independent dataset, will help the clinical interpretation of scores for BCpatients.
Authors: Micha J Pilz; Eva-Maria Gamper; Fabio Efficace; Juan I Arraras; Sandra Nolte; Gregor Liegl; Matthias Rose; Johannes M Giesinger Journal: BMC Public Health Date: 2022-05-24 Impact factor: 4.135
Authors: Teresa C O Tsui; Maureen Trudeau; Nicholas Mitsakakis; Sofia Torres; Karen E Bremner; Doyoung Kim; Aileen M Davis; Murray D Krahn Journal: PLoS One Date: 2022-02-04 Impact factor: 3.240
Authors: Marloes E Clarijs; Jacob Thurell; Friedrich Kühn; Carin A Uyl-de Groot; Elham Hedayati; Maria M Karsten; Agnes Jager; Linetta B Koppert Journal: Cancers (Basel) Date: 2021-05-12 Impact factor: 6.639